Metformin, phase 2
Metformin
MS, type not stated · phase 2 · 30 participants
Main results due Jan 2027
Relapses
Assembled by software from public sources.
Metformin
MS, type not stated · phase 2 · 30 participants
Main results due Jan 2027
Relapses
Ublituximab
Relapsing MS · phase 3 · 800 participants
Main results due Jan 2027
Relapses
Frexalimab
Relapsing MS · phase 3 · 1,655 participants
Main results due May 2027
Relapses
| Area | Due | Trial | Tests | Type of MS | Phase | Participants |
|---|---|---|---|---|---|---|
| 2027 | ||||||
| Relapses | Dec 2027 | TOTEM-RRMS | Testosterone | Relapsing MS | phase 2 | 40 |
| 2029 | ||||||
| Relapses | Jul 2029 | Remibrutinib, phase 3 | Remibrutinib | Relapsing MS | phase 3 | 400 |
| 2030 | ||||||
| Relapses | Jan 2030 | Ublituximab, phase 3 | Ublituximab | Relapsing MS | phase 3 | 240 |
| Relapses | Aug 2030 | BEAT-MS | Stem cell transplantation | Relapsing and progressive MS | phase 3 | 156 |
| 2031 | ||||||
| Relapses | Jun 2031 | DESIRE MS | Stopping or reducing treatment | Relapsing and progressive MS | phase 3 | 250 |